LabCorp Pens Alliance With XDx's AlloMap Organ-Rejection Test

Terms of the deal call for more than 1,700 LabCorp facilities to be XDx's "preferred third-party non-hospital provider" for phlebotomy and specimen processing for all AlloMap gene-expression tests conducted in North America.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.